Roche, Alnylam Ink Potential $2.8B RNAi Partnership for Hypertension
BioSpace
JULY 23, 2023
With an upfront payment of $310 million in cash, Roche is partnering with Alnylam to develop the latter’s RNA interference candidate zilebesiran for hypertension patients with high cardiovascular risk.
Let's personalize your content